G1 Therapeutics (GTHX) Company Total Revenue

Corporate emblem and logo of G1 Pharma (GTHX)

G1 Therapeutics, Inc. (GTHX) generates its primary revenue from the supply of Cosela to lung cancer patients. The company's sales volume confirms its financial stability, with the current metric standing at 0.06. Growth is driven by the creation of a closed-loop supply chain of this unique drug for oncology centers. Cash flow stability is maintained through the expansion of distribution across Europe and Asia.

GTHX - G1 Therapeutics Inc. Company Revenue over the range 07/04/2022 - 09/28/2024

Analytical breakdowns for G1 Therapeutics Inc. (GTHX)

- stock value and consensus price forecast:
- market capitalization details:
General company analysis:G1 Pharma - GTHX
Mass-produced product of G1 Therapeutics

For the biotech sector, G1 Therapeutics, Inc. (GTHX) critically requires the expansion of Cosela's therapeutic indications to overcome revenue stagnation and liquidity shortages. Analyzing the company's sales performance, investors assess the real market share stripped of market noise, where growth in sales volumes confirms leadership while simultaneously signaling a risk of margin compression due to operating expenses.